Show simple item record

dc.contributor.authorJones, Angus G.en
dc.contributor.authorMcDonald, Timothy J.en
dc.contributor.authorShields, Beverley Men
dc.contributor.authorHill, Anita V.en
dc.contributor.authorHyde, C. J.en
dc.contributor.authorKnight, Bridget A.en
dc.contributor.authorHattersley, Andrew T.en
dc.contributor.authorPriba Study Groupen
dc.date.accessioned2016-01-19T12:38:28Zen
dc.date.available2016-01-19T12:38:28Zen
dc.date.issued2015-08-04en
dc.identifier.citationDiabetes Care. 2015 Aug 4. [Epub ahead of print]en
dc.identifier.issn1935-5548en
dc.identifier.pmid26242184en
dc.identifier.doi10.2337/dc15-0258en
dc.identifier.urihttp://hdl.handle.net/11287/594002en
dc.description.abstractOBJECTIVE: To assess whether clinical characteristics and simple biomarkers of beta-cell failure are associated with individual variation in glycemic response to GLP-1 receptor agonist (GLP-1RA) therapy in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: We prospectively studied 620 participants with type 2 diabetes and HbA1c >/=58 mmol/mol (7.5%) commencing GLP-1RA therapy as part of their usual diabetes care and assessed response to therapy over 6 months. We assessed the association between baseline clinical measurements associated with beta-cell failure and glycemic response (primary outcome HbA1c change 0-6 months) with change in weight (0-6 months) as a secondary outcome using linear regression and ANOVA with adjustment for baseline HbA1c and cotreatment change. RESULTS: Reduced glycemic response to GLP-1RAs was associated with longer duration diabetes, insulin cotreatment, lower fasting C-peptide, lower postmeal urine C-peptide-to-creatinine ratio, and positive GAD or IA2 islet autoantibodies (P </= 0.01 for all). Participants with positive autoantibodies or severe insulin deficiency (fasting C-peptide </=0.25 nmol/L) had markedly reduced glycemic response to GLP-1RA therapy (autoantibodies, mean HbA1c change -5.2 vs. -15.2 mmol/mol (-0.5 vs. -1.4%), P = 0.005; C-peptide <0.25 nmol/L, mean change -2.1 vs. -15.3 mmol/mol (-0.2 vs. -1.4%), P = 0.002). These markers were predominantly present in insulin-treated participants and were not associated with weight change. CONCLUSIONS: Clinical markers of low beta-cell function are associated with reduced glycemic response to GLP-1RA therapy. C-peptide and islet autoantibodies represent potential biomarkers for the stratification of GLP-1RA therapy in insulin-treated diabetes.en
dc.language.isoEngen
dc.publisherDiabetes Careen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/26242184en
dc.titleMarkers of beta-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetesen
dc.typeJournal Articleen
dc.identifier.journalDiabetes careen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record